Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCN8440 | Glaucocalyxin B |
| 1. Glaucocalyxin B alleviates lipopolysaccharide-induced Parkinson's disease by inhibiting TLR/NF-κB and activating Nrf2/HO-1 Pathway. 2. Glaucocalyxin B is a potent NF-κB inhibitor for Alzheimer's disease treatment. 3. Glaucocalyxin B shows sensitization of gastric cancer cells to alkylating agents via cell cycle arrest and enhances cell death. 4. Glaucocalyxin B induces apoptosis and autophagy in human cervical cancer cells. 5. Glaucocalyxin B has anti-inflammatory effects, it exhibits neuroprotective effect by preventing over-activated microglia induced neurotoxicity in a microglia/neuron co-culture model. | |
| BCN8392 | Ginsenoside Ra1 |
| 1. Ginsenoside Ra1 shows significant inhibitory effects on protein tyrosine kinase (PTK) activation induced by hypoxia/reoxygenation (H/R). | |
| BCN8547 | Dihydroartemisinic acid |
| 1. Dihydroartemisinic acid is a precursor to the antimalarial agent artemisinin. | |
| BCN8564 | Lancifodilactone F |
| 1. Lancifodilactone F exerts minimal cytotoxicity against C8166 cells (CC50 > 200 microg/mL) and shows anti-HIV activity with EC50 = 20.69 +/- 3.31 microg/mL and a selectivity index > 6.62. | |
| BCN8688 | Licochalcone E |
| 1. Licochalcone E is a potential LXRβ agonist. 2. Licochalcone E may be used for the treatment of hepatotoxicity, and primarily exhibits its protective role through a PPARγ/NF-κB-mediated pathway. 3. Licochalcone E exhibits potential chemopreventive effects and warrants further developed as a chemotherapeutic agent against oral cancer. 4. Licochalcone E exhibits potent anti-inflammatory property in 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse ear edema and lipopolysaccharide (LPS)-stimulated RAW 264.7 murine macrophage models. 5. Licochalcone E suppresses lung metastasis in the 4T1 mammary orthotopic cancer model. 6. Licochalcone E shows potent antimicrobial property against Staphylococcus aureus. 7. Licochalcone E is a potential activator of the Nrf2/ARE-dependent pathway and is therapeutically relevant not only to oxidative-stress-related neurodegeneration but also inflammatory responses of microglial cells both in vitro and in vivo. 8. Licochalcone E has an antidiabetic effect, it increases the levels of PPARγ expression, at least in part, via the stimulation of Akt signals and functions as a PPARγ partial agonist. 9. Licochalcone E reduces chronic allergic contact dermatitis and inhibits IL-12p40 production through down-regulation of NF-kappa B. 10. Licochalcone E shows cytotoxicity against the human tumor cell lines. | |
| BCN3860 | o-Methoxycinnamaldehyde |
| o-Methoxycinnamaldehyde from cinnamon has antibiotic activity, it is a competitive inhibitor against CYP1A2 while it was a mixed type inhibitor against CYP2E. | |
| BCN8592 | Licoflavone B |
| 1. Licoflavone B has schistosomicidal activity, it showed high S. mansoni ATPase (IC50 of 23.78 uM) and ADPase (IC50 of 31.50 uM) inhibitory activities. | |
| BCN8418 | Butylparaben |
| 1. The handsheet paper containing laccase and butyl 4-hydroxybenzoate shows a greater efficiency against the growth of bacteria. | |
